El medio RPMI 1640 lo desarrolló el equipo de Moore en el Instituto Roswell Park Memorial en 1966. Se formuló una modificación del medio McCoy 5A para sostener las células linfoblastoides en cultivo en suspensión, pero desde entonces se ha demostrado que sirve de soporte para una amplia variedad de células que necesitan anclaje. Originalmente indicado para utilizar con un complemento sérico, se ha demostrado que el RPMI 1640 respalda diversas líneas celulares en ausencia de suero. También se ha utilizado ampliamente en protocolos de fusión y en el crecimiento de células híbridas. Este medio es adecuado para el cultivo de leucocitos humanos sanos y neoplásicos.
Otras notas
This RPMI-1640 medium is supplemented with L-Ala-L-Gln dipeptide. This provides a more stable form of glutamine for cell culture. Free amino acid L-glutamine is known to be unstable in cell culture.
Información legal
StableCell is a trademark of Sigma-Aldrich Co. LLC
International journal of molecular sciences, 22(6) (2021-04-04)
A high platelet count is associated with a poor prognosis in ovarian cancer (OvCa). Despite good clinical responses with platinating agents in combination with taxanes, numerous OvCa patients relapse due to chemotherapy resistance. Here, we report that treatment of OvCa
microRNA (miRNA) dysregulation is a common feature of cancer cells, but the complex roles of miRNAs in cancer are not fully elucidated. Here, we used functional genomics to identify oncogenic miRNAs in non-small cell lung cancer and evaluate their impact
Hepatocellular carcinoma (HCC) is a deadly form of liver cancer with high mortality worldwide. Unfortunately, the large heterogeneity of this disease makes it difficult to develop effective treatment strategies. Cellular network analyses have been employed to study heterogeneity in cancer
Perturbation in JAK-STAT signaling has been reported in the pathogenesis of cutaneous T cell lymphoma (CTCL). JAK3 is predominantly associated with the intra-cytoplasmic part of IL-2Rγc located in the plasma membrane of hematopoietic cells. Here we demonstrate that JAK3 is
Albumin has a serum half-life of 3 weeks in humans. This feature can be used to improve the pharmacokinetics of shorter-lived biologics. For instance, an albumin-binding domain (ABD) can be used to recruit albumin. A prerequisite for such design is that
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
